查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1198463

脊髓刺激器市场——COVID-19 的增长、趋势、影响和预测 (2023-2028)

Spinal Cord Stimulation Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内 (2022-2027)，脊髓刺激器市场预计将以 8.5% 的复合年增长率增长。

在 COVID-19 大流行期间，脊髓刺激器市场受到供应链问题的不利影响。 各种研究提供了有关 Covid 对脊髓刺激的影响的见解。 例如，2021 年 8 月，一项名为“COVID-19 大流行对英国等待脊髓刺激手术的患者的影响”的研究发表了。 根据多中心患者调查，脊髓刺激 (SCS) 是慢性顽固性神经性疼痛的推荐治疗方法。 在 COVID-19 流行期间，择期手术已无限期推迟，以提供处理紧急情况的能力，并避免将择期手术患者暴露于 COVID-19。 因此，此类研究可以深入了解大流行对南海的负面影响。

脊柱疾病和慢性背痛的患病率上升以及医疗报销的可用性等因素是市场增长的主要驱动力。 国家脊髓损伤统计中心 2021 年 6 月的一份报告估计，美国约有 296,000 人患有脊髓损伤。 在这一人群中，大约 78% 的脊髓损伤发生在男性，其余 22% 发生在女性。 在这 34,683 名样本中，最常见的脊髓损伤原因是车祸 (32%)、跌倒 (23.1%)、枪伤 (15.2%)、摩托车事故 (6.1%) 和潜水 (5.7%)。

同样，2021 年 8 月，宣布了一项名为“脊髓损伤”的研究，指出全世界每年有 25 万至 50 万患者遭受脊髓损伤。 这些案件中的大多数是由于暴力和车祸等可预防的原因造成的。 它还指出，美国每年约有 17,000 例新的脊髓损伤 (SCI)。 同样，腰痛也是市场增长因素之一。 例如，2021 年 11 月发表的一项题为“急性和慢性腰痛的干预措施”的研究。 2021 年修订版”指出，腰痛 (LBP) 仍然是一种具有社会后果的肌肉骨骼疾病。 在世界范围内，背痛非常普遍，是导致残疾的主要原因。 因此，脊髓损伤和腰痛的增加可能会增加脊髓刺激器的消耗，从而增加市场增长。

对脊髓刺激器的需求正在增加。 例如，2022 年 2 月，世界医疗保健技术领导者之一美敦力公司报告了印度的第一个临床程序，其 Intellis 脊髓刺激 (SCS) 平台。 它是世界上最小的 SCS 设备，用于治疗某些类型的慢性顽固性疼痛。 在新兴国家使用这种技术先进的产品可能会促进未来的市场增长。

报销也是推动市场增长的因素之一。 例如，在 2021 年 12 月发表的题为“2022 年全国门诊手术中心 (ASC) 的平均支付率”的报告中，带有 Perc 导线的 SCS 植入物（插入或更换脊髓神经刺激器脉衝发生器或接收器，直接或电感耦合）赎回成本为 24,424 美元。 同样，用于植入神经刺激器电极、板/桨和硬膜外的椎板切除术的费用为 17,146 美元。 因此，上述因素将增加未来市场的增长。

但是，与脊髓刺激器相关的风险可能会阻碍市场增长。

脊髓刺激器市场趋势

在预测期内，退行性椎间盘疾病细分市场预计将占据较大的市场份额

退行性椎间盘疾病 (DDD) 是指脊柱中一个或多个椎间盘因年龄增长而退化，导致背部和颈部疼痛。 流行程度的提高和产品批准等因素正在推动这一细分市场的增长。

关于椎间盘退变的各种研究已经发表。 例如，2022 年 2 月发表的一项题为“腰椎退行性椎间盘疾病”的研究表明，大多数椎间盘退变是无症状的，因此很难真正了解患病率。 同一份文件还指出，椎间盘退变和椎间盘突出的定义并不统一，因此很难在多项研究中检验实际患病率。 对 20 项评估无症状个体磁共振成像 (MRI) 研究的荟萃分析报告了各个层面的椎间盘异常。 20% 至 83% 的信号强度损失，10% 至 81% 的椎间盘突出，3% 至 63% 的椎间盘突出（0% 至 24% 的椎间盘突出），3% 至 56% 的椎间盘狭窄 %，环状撕裂范围为 6 % 至 56%。

同样，2021 年 8 月发表的另一项名为“颈椎间盘退变”的研究表明，颈椎椎间盘退变与腰椎一样，是一种与年龄相关的自然现象。。 同一份文件指出，无论患者的症状如何，宫颈 DDD 的患病率都会随着年龄的增长而增加。 四分之一的 40 岁以下患者有椎间盘退变或某一节段狭窄的证据。 这一证据见于同一人群中大约 60% 的 40 岁以上患者。 因此，DDD 的患病率很普遍，预计未来会增加。

临床试验是推动市场增长的另一个因素。 例如，2021 年 2 月，Mesoblast Limited 是治疗炎症性疾病的同种异体细胞药物的全球领导者之一，它宣布将治疗因退行性椎间盘疾病 (DDD) 引起的慢性腰痛，这种疾病对阿片类药物等可用疗法无效。已从美国食品和药物管理局 (FDA) 组织和高级治疗办公室 (OTAT) 收到关于 rexlemestrocel-L 在 CLBP 患者中的第 3 期计划的反馈。 此类临床试验将增加市场创新，并有望在未来增长。 因此，由于上述因素，未来市场可能会增长。

北美有望在预测期内主导市场

市场研究的主要驱动因素是脊髓损伤 (SCI) 的增加、该地区的产品发布和研究。

各种研究提供了对北美地区脊髓损伤 (SCI) 流行病学的深入了解。 例如，在 2021 年，宣布了一项名为“制定加拿大脊髓损伤最佳实践 (Can-SCIP) 指南”的研发工作。 根据方法和概述，可用的 SCI 特定临床实践指南 (CPG) 解决了特定的疾病、健康状况或连续护理的一部分，但个人的护理之旅。它说它不能解决出现的每一个重要的临床问题. 为了解决这一差距，SCI 专家组成的专家小组召集起来製定加拿大脊髓损伤最佳实践 (Can-SCIP) 指南。 因此，标准指南可以提供更好的方法来改善治疗结果，而高成功率可能会推动脊髓刺激器的采用。

产品发布也是该地区增长的一个因素。 2021 年 1 月，波士顿科学公司宣布其脊髓刺激器 (SCS) 系统产品组合 WaveWriter Alpha 限量上市。 由四个 MRI 条件、支持蓝牙的可充电和不可充电植入式脉衝发生器 (IPG) 组成的统一产品组合提供了无与伦比的个性化服务，并且在 SCS 上首次推出了速效亚感知疗法 (FAST)，旨在提供深度、数分钟内无感觉的疼痛缓解。 此类产品的推出将促进该地区的市场增长。

产品批准也是市场增长的一个因素。 例如，2021 年 7 月，美国食品药品监督管理局 (FDA) 批准了 Senza 脊髓刺激 (SCS) 系统。 这是一种可植入、可充电的脊髓刺激系统，旨在治疗难以控制的躯干和四肢的长期（慢性）疼痛。

因此，上述因素有望推动未来的市场增长。

脊髓刺激器市场竞争对手分析

市场部分分散，由几家大型企业组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 目前主导市场的公司包括 Abbott Laboratories, Inc.、Boston Scientific Corporation、Saluda Medical Pty Ltd.、Medtronic 和 NEVRO CORP 等公司。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第1章介绍

  • 研究假设和市场定义
  • 调查范围

第2章研究方法论

第 3 章执行摘要

第4章市场动态

  • 市场概览
  • 市场驱动因素
    • 脊柱疾病的负担越来越重
    • 医疗保险报销的可用性
  • 市场製约因素
    • 与脊髓刺激器相关的风险
  • 五力分析分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：100 万美元）

  • 按设备类型
    • 可充电
    • 不可充电
  • 通过申请
    • 椎间盘退变
    • 背痛
    • 椎间盘手术失败
    • 其他
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第6章竞争格局

  • 公司简介
    • Abbott Laboratories, Inc.
    • Beijing PINS Medical Co., Ltd.
    • Boston Scientific Corporation
    • Cirtec
    • Gimer Medical
    • Medtronic
    • Nalu Medical
    • NEVRO CORP.
    • Saluda Medical Pty Ltd.
    • Stimwave Technologies. Inc.
    • SYNAPSE BIOMEDICAL INC.

第7章 市场机会与今后动向

简介目录
Product Code: 90522

The Spinal Cord Stimulation Devices Market is projected to register a CAGR of 8.5% during the forecast period (2022-2027).

During the COVID-19 pandemic, the spinal cord stimulation devices market was adversely affected due to supply chain issues. Various research studies have provided insight into the impact of Covid on spinal cord stimulations. For instance, in August 2021, a research study published titled "The Impact of the COVID-19 Pandemic on Patients Awaiting Spinal Cord Stimulation Surgery in the United Kingdom: A Multi-Center Patient Survey" stated that spinal cord stimulation (SCS) is a recommended treatment for chronic refractory neuropathic pain. During the COVID-19 pandemic, elective procedures have been postponed indefinitely both to provide capacity to deal with the emergency caseload and to avoid exposure of elective patients to COVID-19. Hence, such studies provide insight into the negative impact of the pandemic on SCS.

Factors such as the rising prevalence of spinal disorders and chronic lower back pains coupled with the availability of medical reimbursements are key factors for the growth of the market. According to the National Spinal Cord Injury Statistical Center June 2021 report, it is estimated that about 296,000 people in the United States are living with a spinal cord injury. Of this population, about 78% of spinal cord injury cases occur in males, while the remaining 22% occur in females. The most common causes of SCI in this sample of 34,683 include auto accidents (32%), falls (23.1%), gunshot wounds (15.2%), motorcycle accidents (6.1%), and Diving (5.7%).

Similarly, in August 2021, a research study published titled "Spinal Cord Injuries" stated that globally between 250,000 and 500,000 patients each year suffer a spinal cord injury. Most of these cases are due to preventable causes such as violence and motor vehicle accidents. The same source stated that in the United States, there are approximately 17,000 new cases of spinal cord injuries (SCI) each year. Similarly, lower back pains are another factor in the growth of the market. For instance, in November 2021, a research study published titled "Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021" stated that low back pain (LBP) remains a musculoskeletal condition with an adverse societal impact. Globally, LBP is highly prevalent and a leading cause of disability. Hence, increasing spinal cord injury and lower back pain would increase the consumption of spinal cord stimulation devices and will increase the market growth.

The demand for spinal cord stimulators is increasing. For instance, in February 2022, Medtronic plc, one of the global leaders in healthcare technology, reported the first clinical procedure in India with the Intellis spinal cord stimulation (SCS) platform. It is one of the world's smallest SCS devices for the management of certain types of chronic intractable pain. Such use of technologically advanced products in developing countries would increase market growth in the upcoming future.

Reimbursement is another factor in the growth of the market. For instance, in the December 2021 report published titled "2022 National Average Payment Rate for Ambulatory Surgery Center (ASC)," the reimbursement cost for SCS Implant with Perc Leads (Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling) is USD 24,424. Similarly, the cost for laminectomy for implantation of neurostimulator electrodes, plate/paddle, and epidural is USD 17,146. Thus, the abovementioned factors will increase market growth in the upcoming future.

However, the risk associated with spinal cord stimulation devices would hinder the market growth.

Spinal Cord Stimulation Devices Market Trends

Degenerative Disk Disease Segment is Expected to Hold a Significant Market Share Over the Forecast Period

Degenerative disc disease (DDD) is a condition where one or more discs in the spine deteriorate due to age, which results in back or neck pain. Factors such as increasing prevalence and product approvals are driving the growth of this segment.

Various research studies have been published on degenerative disc diseases. For instance, in February 2022, a research study published titled "Lumbar Degenerative Disk Disease" stated that most intervertebral disc degenerations are asymptomatic, making a true understanding of the prevalence difficult. The same source stated that, due to the lack of uniformity in the definitions of disc degenerations and disc herniations, the actual prevalence of the disease is difficult to review across multiple studies. In a meta-analysis of 20 studies evaluating the magnetic resonance imaging (MRI) of asymptotic individuals, the reported disc abnormalities at any level were: 20% to 83% for a reduction in signal intensity, 10% to 81% for disc bulges, 3% to 63% for disc protrusion (versus 0% to 24% for disc extrusion), 3% to 56% for disc narrowing, and 6% to 56% with annular tears.

Similarly, another research published in August 2021, titled "Cervical Degenerative Disc Disease," stated that similar to the lumbar spine, cervical disc degeneration is a naturally occurring age-related phenomenon. The same source stated that the prevalence of cervical DDD increases with age regardless of the patient's symptomatology. A quarter of patients less than the age of 40 showed evidence of disk degeneration or narrowing at one level. This evidence was found in about 60% of patients in the same population who were greater than 40 years old. Hence, the prevalence of DDD is common and will increase in the upcoming future.

Clinical trials are another factor in the growth of the market. For instance, in February 2021, Mesoblast Limited, one of the global leaders in allogeneic cellular medicines for inflammatory diseases, received feedback from the United States Food & Drug Administration's (FDA) Office of Tissues and Advanced Therapies (OTAT) on the Phase III program of rexlemestrocel-L in patients with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids. Such clinical trials increase the innovation in the market, which increases the growth of the market in the upcoming future. Hence, due to the abovementioned factors, the market is likely to grow in the future.

North America is Expected to Dominate the Market Over the Forecast Period

The key factors propelling the market studied are increasing spinal cord injuries (SCI), product launches, and research studies in the region.

Various research studies have provided insight into the epidemiology of spinal cord injury (SCI) in the North American region. For instance, in 2021, a research study published titled "Development of the Canadian Spinal Cord Injury Best Practice (Can-SCIP) Guideline: Methods and overview" stated that the available SCI-specific clinical practice guidelines (CPG) address specific impairments, health conditions, or a segment of the care continuum, however, fail to address all the important clinical questions arising throughout an individual's care journey. To address this gap, an interprofessional panel of experts in SCI convened to develop the Canadian Spinal Cord Injury Best Practice (Can-SCIP) Guideline. Hence, standard guidelines could provide better methods to increase the treatment outcomes, which would increase the adoption of spinal cord stimulation devices due to a higher success rate.

Product launches are another factor in the growth of the region. In January 2021, Boston Scientific reported a limited market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable, and non-rechargeable implantable pulse generators (IPGs) provides uncompromised personalization, and for the first time in SCS, Fast Acting Sub-perception Therapy (FAST) is designed to deliver profound paresthesia-free pain relief in minutes. Such product launches would increase the market growth in the region.

Product approval is another factor in the growth of the market. For instance, in July 2021, Food and Drug Administration (FDA) approved Senza Spinal Cord Stimulation (SCS) System. It is an implanted, rechargeable spinal cord stimulation system intended to treat long-term (chronic) pain in the trunk or limbs that is difficult to manage.

Hence, the abovementioned factors would increase market growth in the upcoming future.

Spinal Cord Stimulation Devices Market Competitor Analysis

The market is partially fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Abbott Laboratories, Inc., Boston Scientific Corporation, Saluda Medical Pty Ltd., Medtronic, and NEVRO CORP., among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Spinal Disorders
    • 4.2.2 Availability of Medical Reimbursements
  • 4.3 Market Restraints
    • 4.3.1 Risks Associated with Spinal Cord Stimulation Devices
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Device Type
    • 5.1.1 Rechargeable
    • 5.1.2 Non-rechargeable
  • 5.2 By Application
    • 5.2.1 Degenerative Disk Disease
    • 5.2.2 Failed Back Syndrome
    • 5.2.3 Unsuccessful Disk Surgery
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories, Inc.
    • 6.1.2 Beijing PINS Medical Co., Ltd.
    • 6.1.3 Boston Scientific Corporation
    • 6.1.4 Cirtec
    • 6.1.5 Gimer Medical
    • 6.1.6 Medtronic
    • 6.1.7 Nalu Medical
    • 6.1.8 NEVRO CORP.
    • 6.1.9 Saluda Medical Pty Ltd.
    • 6.1.10 Stimwave Technologies. Inc.
    • 6.1.11 SYNAPSE BIOMEDICAL INC.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS